Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$73.79 +1.3%	$73.55	$62.75 ▼ $87.68	$228.84B	0.41	5.11 million shs	3.43 million shs
BMY Bristol-Myers Squibb	$60.10 +2.0%	$58.55	$39.35 ▼ $63.33	$121.96B	0.43	12.75 million shs	10.79 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
HSBC HSBC	$57.77 -1.0%	$55.68	$39.04 ▼ $61.88	$205.71B	0.51	1.66 million shs	1.30 million shs
LLY Eli Lilly and Company	$820.30 -0.2%	$844.31	$711.40 ▼ $972.53	$777.78B	0.34	3.31 million shs	2.12 million shs
NVO Novo Nordisk A/S	$69.36 -1.1%	$82.33	$69.11 ▼ $148.15	$311.23B	0.42	5.56 million shs	5.85 million shs
PFE Pfizer	$25.20 +0.8%	$26.06	$24.48 ▼ $31.54	$142.93B	0.61	39.04 million shs	32.32 million shs
SNPS Synopsys	$437.95 -1.9%	$485.62	$425.73 ▼ $624.80	$67.72B	1.16	1.05 million shs	941,520 shs
XLV Health Care Select Sector SPDR Fund	$144.52 -0.3%	$146.33	$135.95 ▼ $159.64	$38.15B	0.68	7.51 million shs	6.21 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.17%	-4.81%	-3.40%	+9.93%	+6.71%
BMY Bristol-Myers Squibb	-0.47%	-2.48%	+1.11%	+2.11%	+10.60%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
HSBC HSBC	+0.11%	+1.34%	+1.04%	+18.46%	+49.73%
LLY Eli Lilly and Company	-0.57%	-2.51%	-8.90%	+4.98%	+5.58%
NVO Novo Nordisk A/S	-2.18%	-10.87%	-22.83%	-19.68%	-45.19%
PFE Pfizer	-0.56%	-4.26%	-6.37%	-5.89%	-9.79%
SNPS Synopsys	-0.82%	-0.84%	-2.56%	-9.10%	-22.17%
XLV Health Care Select Sector SPDR Fund	+0.16%	-1.39%	-2.63%	+4.33%	-1.85%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.8019 of 5 stars	2.6	5.0	1.7	0.0	2.9	0.0	1.3
BMY Bristol-Myers Squibb	3.8905 of 5 stars	1.2	3.0	4.2	4.0	3.6	3.3	0.0
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HSBC HSBC	2.6644 of 5 stars	0.0	5.0	1.7	0.0	3.0	0.0	1.9
LLY Eli Lilly and Company	4.8039 of 5 stars	2.4	5.0	3.3	4.0	3.4	2.5	1.9
NVO Novo Nordisk A/S	4.79 of 5 stars	4.4	5.0	1.7	0.0	2.4	0.0	4.4
PFE Pfizer	4.9866 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
SNPS Synopsys	4.882 of 5 stars	4.5	3.0	0.0	3.0	3.7	2.5	2.5
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$89.75	21.63% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-3.73% Downside
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
HSBC HSBC	2.60	Moderate Buy	N/A	N/A
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	23.09% Upside
NVO Novo Nordisk A/S	2.80	Moderate Buy	$145.25	109.43% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	26.67% Upside
SNPS Synopsys	2.92	Moderate Buy	$638.58	45.81% Upside
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$144.52	N/A

Current Analyst Ratings Breakdown

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	NVO Novo Nordisk A/S	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/6/2025	HSBC HSBC	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/5/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$970.00 ➝ $1,100.00
3/4/2025	HSBC HSBC	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
3/3/2025	NVO Novo Nordisk A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/27/2025	SNPS Synopsys	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$655.00 ➝ $653.00
2/27/2025	SNPS Synopsys	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$650.00 ➝ $650.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.23	$6.26 per share	11.79	$13.18 per share	5.60
BMY Bristol-Myers Squibb	$48.30B	2.53	$6.34 per share	9.48	$8.08 per share	7.44
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
HSBC HSBC	$67.40B	3.05	$8.10 per share	7.13	$53.68 per share	1.08
LLY Eli Lilly and Company	$45.04B	17.27	$13.37 per share	61.34	$15.05 per share	54.50
NVO Novo Nordisk A/S	$290.40B	1.07	$3.22 per share	21.57	$4.64 per share	14.95
PFE Pfizer	$63.63B	2.25	$3.95 per share	6.38	$15.81 per share	1.59
SNPS Synopsys	$6.07B	11.15	$11.35 per share	38.60	$58.54 per share	7.48
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	32.65	14.76	1.42	13.01%	32.23%	12.31%	4/29/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.87	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
HSBC HSBC	$23.53B	$6.20	9.32	8.11	1.05	16.17%	12.20%	0.79%	4/29/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	70.05	26.36	1.40	23.51%	85.24%	16.19%	5/1/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.29	21.08	14.88	0.90	34.81%	84.68%	26.29%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.87	8.32	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SNPS Synopsys	$2.26B	$13.52	30.16	33.53	3.23	36.12%	20.48%	13.51%	5/20/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.25	∞	N/A	N/A	N/A	N/A	N/A

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	AZN AstraZeneca	$1.10	N/A	N/A	N/A	N/A	N/A
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
2/19/2025	Q4 2024	HSBC HSBC	$1.41	$1.45	+$0.04	$0.10	$13.79 billion	$11.56 billion
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/5/2025	Q4 2024	NVO Novo Nordisk A/S	$0.88	$0.91	+$0.03	$0.91	N/A	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.79%	+1.98%	91.15%	N/A
BMY Bristol-Myers Squibb	$2.48	4.13%	+6.38%	N/A	17 Years
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
HSBC HSBC	$7.18	12.43%	+40.49%	115.81%	N/A
LLY Eli Lilly and Company	$6.00	0.73%	+15.21%	51.24%	11 Years
NVO Novo Nordisk A/S	$1.57	2.26%	+25.26%	47.72%	N/A
PFE Pfizer	$1.72	6.83%	+2.50%	121.99%	16 Years
SNPS Synopsys	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	$2.29	1.58%	N/A	N/A	N/A

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
2/19/2025	HSBC HSBC	quarterly	$1.80	5.8%	3/7/2025	3/7/2025	4/25/2025
2/5/2025	NVO Novo Nordisk A/S	semi-annual	$0.7874	1.2%	3/31/2025	3/31/2025	4/8/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
BMY Bristol-Myers Squibb	2.90	1.25	1.15
GRCL Gracell Biotechnologies	0.02	7.73	7.73
HSBC HSBC	0.69	0.88	0.96
LLY Eli Lilly and Company	2.00	1.15	0.97
NVO Novo Nordisk A/S	0.62	0.74	0.55
PFE Pfizer	0.63	1.00	0.73
SNPS Synopsys	N/A	2.44	2.30
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BMY Bristol-Myers Squibb	76.41%
GRCL Gracell Biotechnologies	N/A
HSBC HSBC	1.48%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
SNPS Synopsys	85.47%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BMY Bristol-Myers Squibb	0.09%
GRCL Gracell Biotechnologies	28.00%
HSBC HSBC	0.01%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%
SNPS Synopsys	0.62%
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	Optionable
HSBC HSBC	220,861	3.56 billion	3.58 billion	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SNPS Synopsys	19,000	154.62 million	153.56 million	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	263.97 million	N/A	Not Optionable

AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Headlines

Recent News About These Companies

Waters Corporation Stock: Is WAT Outperforming the Healthcare Sector?

March 26 at 7:01 AM | msn.com

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

March 26 at 3:23 AM | americanbankingnews.com

S&P sector rankings as the first quarter of 2025's close is around the corner

March 24, 2025 | msn.com

3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs Data

March 14, 2025 | zacks.com

Merck and 8 More Healthcare Stocks for Nervous Dividend Investors

March 13, 2025 | msn.com

Select Sector SPDR ETFs: Strategic Investment with Sector-Specific Allocations

March 12, 2025 | finance.yahoo.com

Recession Fears Looming? Secure Your Portfolio With These ETFs

March 11, 2025 | zacks.com

Health Care Sector Trying to Bounce Back

March 6, 2025 | theglobeandmail.com

Shifting Tides in Leadership: Markets Play Defense

March 6, 2025 | etftrends.com

Time for Defensive Sector ETFs?

February 27, 2025 | zacks.com

Healthcare best performing sector as market angst builds

February 25, 2025 | marketwatch.com

Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.

February 25, 2025 | msn.com

Health Care Has Been a Top Sector

February 22, 2025 | finance.yahoo.com

What Top-Performing Healthcare Funds Are Buying Now

February 19, 2025 | msn.com

Final Trade: FWONK, XLV, MSFT, PEP

February 13, 2025 | youtube.com

18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard

February 8, 2025 | msn.com

Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025

February 7, 2025 | seekingalpha.com

Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)

February 6, 2025 | seeitmarket.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

February 4, 2025 | zacks.com

Can Health Care ETFs Aid Your Portfolio?

February 3, 2025 | etftrends.com

S&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)

December 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
Missed the Hims & Hers Rally? Clover Health Could Be Next
By Gabriel Osorio-Mazilli | March 5, 2025
View Missed the Hims & Hers Rally? Clover Health Could Be Next
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
By Sarah Horvath | March 3, 2025
View These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
By Thomas Hughes | February 27, 2025
View 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year

AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Company Descriptions

AstraZeneca NASDAQ:AZN

$73.79 +0.95 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$72.92 -0.87 (-1.18%)

As of 07:51 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol-Myers Squibb NYSE:BMY

$60.10 +1.20 (+2.04%)

Closing price 03:59 PM Eastern

Extended Trading

$59.96 -0.13 (-0.22%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

HSBC NYSE:HSBC

$57.77 -0.57 (-0.98%)

Closing price 03:59 PM Eastern

Extended Trading

$57.98 +0.21 (+0.37%)

As of 07:28 PM Eastern

HSBC Holdings plc provides banking and financial services worldwide. The company operates through Wealth and Personal Banking, Commercial Banking, and Global Banking and Markets segments. The Wealth and Personal Banking segment offers retail banking and wealth products, including current and savings accounts, mortgages and personal loans, credit and debit cards, and local and international payment services; and wealth management services comprising insurance and investment products, global asset management services, investment management, and private wealth solutions. This segment serves personal banking and high net worth individuals. The Commercial Banking segment provides credit and lending, treasury management, payment, cash management, commercial insurance, and investment services; commercial cards; international trade and receivables finance services; foreign exchange products; capital raising services on debt and equity markets; and advisory services. It serves small and medium sized enterprises, mid-market enterprises, and corporates. The Global Banking and Markets segment offers financing, advisory, and transaction services; and credit, rates, foreign exchange, equities, money markets, and securities services; and engages in principal investment activities. It serves government, corporate and institutional clients, and private investors. HSBC Holdings plc was founded in 1865 and is headquartered in London, the United Kingdom.

Eli Lilly and Company NYSE:LLY

$820.30 -1.37 (-0.17%)

Closing price 03:59 PM Eastern

Extended Trading

$815.45 -4.85 (-0.59%)

As of 07:57 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$69.36 -0.81 (-1.15%)

Closing price 03:59 PM Eastern

Extended Trading

$69.36 +0.01 (+0.01%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)

Closing price 03:59 PM Eastern

Extended Trading

$25.14 -0.07 (-0.26%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Synopsys NASDAQ:SNPS

$437.95 -8.28 (-1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$436.47 -1.48 (-0.34%)

As of 07:45 PM Eastern

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$144.52 -0.45 (-0.31%)

Closing price 04:10 PM Eastern

Extended Trading

$144.31 -0.21 (-0.15%)

As of 07:56 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Earnings

Compare Dividends

Latest AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, BMY, LLY, GRCL, XLV, HSBC, NVO, PFE, and SNPS Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools